Multiple Myeloma Awareness Month: the current and future landscape
March is Multiple Myeloma (MM) Awareness Month, which raises awareness, action, and amplifies the voices of individuals impacted by MM,…
Oncology
-
-
Targeted therapies to join chemo as oncology treatment backbone
In recent years, the oncology sector has undergone a fundamental shift away from chemotherapy-dominant treatment towards the use of regimens…
-
Theranostics earmarked as “the future” of radiopharmaceuticals
As the oncology market enters a new era of growth, targeted therapies across several modalities are transforming the treatment paradigm.…
-
JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition
AstraZeneca has agreed to acquire Boston-based Modella AI as part of a strategy to speed up drug development across its…
-
JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree
Revolution Medicines has dominated the build-up to the 2026 J.P. Morgan Healthcare Conference, as media reports swirl around a potential…
-
Aktis Oncology kicks 2026 IPO cycle off with $210m target
The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a…
-
Genmab shelves Phase III lung cancer candidate
Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including…
-
Precision medicine approaches needed in oncology to match evolving SoC
As the standard of care (SoC) for new drugs in oncology continues to improve, trials need to be designed with…
-
Crescent and Kelun-Biotech swap cancer asset rights in double deal
US company Crescent Biopharma and China-based Kelun-Biotech have partnered to exchange the rights to two of their cancer drugs as…
-
USPTO grants patent to Genprex’s Reqorsa gene therapy
The US Patent and Trademark Office (USPTO) has granted a patent to Genprex for the use of its Reqorsa gene…
